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Purpose/Objective: To compare complication rate, outcome, and 
compliance of patients (pts) treated with pulsed dose rate (PDR) 
versus low dose rate (LDR) brachytherapy (BRT) following external 
beam radiation therapy (EBRT) for endometrial cancer (EC). 
Materials and Methods: From August 2009 to August 2012, 50 
consecutive pts, undergoing total abdominal hysterectomy, bilateral 
salpingo-oophorectomy for endometrial cancer were treated by 
adjuvant EBRT and intra-cavitary PDR BRT because of invasion of the 
cervical canal. Median age was 68 years. Pathological stage according 
to the FIGO 2010 classification was: 7 IA, 9 IB, 21 II, 1 IIIA, 2 IIIB,9 IIIC, 
1 IVA. Histology was adenocarcinoma in 35 cases (70%) and other 
histologies in 15 cases (30%). All pts underwent EBRT to the pelvic 
region to a total dose of 45-50 Gy in 25 fractions, with a 3D-RT in 29 
cases (58%), and with IMRT in 21 cases (42%). After EBRT, all pts 
underwent to BRT boost with PDR 192Ir source. The median PDR dose 
(prescribed to 0.5 cm from the vaginal surface) was 9 Gy (1 
application/die delivered by means of 10 or 12 pulses of 0.45 Gy every 
half an hour for 2 days). A cohort of 44 pts with similar clinical 
characteristics and treated by LDR BRT from 1998 to 2006 was 
analyzed and compared. In the LDR group, median age was 67.5 years, 
pathological stage showed 7 IA, 11 IB, 17 II, 3 IIIA, 1 IIIB,5 IIIC and 
histology was adenocarcinoma in 39 cases (89%) and other histologies 
in 5 cases (11%). All pts after EBRT to the pelvic region to a total dose 
of 45-50 Gy in 25 fractions underwent BRT boost with LDR 137Cs 
sources inserted with a customized vaginal moulde (moulage). The 
median LDR dose (prescribed to 0.5 cm from the vaginal surface) was 
13 Gy (range, 10 -15 Gy). Acute and late effects were assessed by the 
RTOG scoring systems in both treatment groups.  
Results: Early toxicity as G1-G2 enteric, urinary and vaginal was 
observed in 14%, 16%, 38% of cases and in 41%, 16%, 36% of cases in 
the PDR and LDR group, respectively. G3 vaginal acute toxicity was 
found in 4% of pts only in PDR group. With a median follow-up of 17 
and 59 months for the PDR and LDR group,1 (2%) and 3 pts (6%) 
developed vaginal-cuff relapse, and 2 (4%) and 3 pts (7%) developed 
distance metastasis, respectively. Late toxicity as G1-2 gastro-enteric, 
urinary and vaginal was observed in 2%, 0%, 12% of cases and in 2%, 
2%, 15% of cases of the PDR and LDR group, respectively.No pts was 
excluded a priori from the both PDR and LDR treatment, and no pts 
interrupted both the PDR and LDR treatment. 
Conclusions: PDR BRT is a safe and effective BRT method in the 
treatment of EC. It combines the physics benefits of dose optimization 
and the radiobiological advantages of LDR BRT. PDR allowed also to 
avoid the exposure of personnel to ionizing radiation making easier 
the patient management. 
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Purpose/Objective: Due to its superior soft-tissue contrast, magnetic 
resonance imaging (MRI) is valuable in image guided interventions like 
brachytherapy (BT). It provides better visualization of the target and 
critical structures at the moment of intervention. At the UMC Utrecht 
we built a dedicated treatment suite equipped with an HDR 
afterloader and a 1.5 T MR scanner, where patient treatment and MRI 
can be combined. Purpose of this combined interventional imaging 
and application approach is to treat patients with 3D MRI guided 
adaptive brachytherapy and to control DVH parameters before start of 
irradiation. In this abstract we describe our first clinical experience 
with MR guided interstitial BT of the orbita/ nasal cavity area. 
Materials and Methods: This study decribes the MRI guided BT 
procedure for 2 patients. Patient 1 received pulsed dose rate (PDR) BT 
on the resection margins after exenteratio orbitae due to a acinic cell 
carcinoma of the lacrimal gland. Patient 2 recieved PDR BT after 
exenteratio orbitae for a local recurrence within 1.5 years of a 
squamous cell carcinoma originating from the oral cavity. Individual 
moulds were made that fitted the patients orbita cavity. Patients 
underwent MR imaging prior to BT. MRI based preplans were made to 
determine catheter trajectories for optimal dose distribution. 
Catheter trajectories were drilled into or glued to the mould and 
patients underwent MR imaging with mould in situ to verify the 
position of the catheters in relation to patients anatomy. The 
catheters were filled with saline solution to make them visible on MRI. 
Preplans were made with the catheter positions visible. Application of 
the mould and the catheters was performed in the MRI-HDR suite to 
verify the mould position and thereafter a definitive dose distribution 
was planned. For patient 1 twelve catheters were inserted up to 36 
mm into the tissue under MR guidance posterior in the orbitacavity. 
For patient 2 fourteen catheters were placed in the mould and 2 
catheters interstitially in the cheek. The accuracy of MRI based 
reconstruction was verified by CT based reconstruction. The following 
tumorcidal dose parameters were evaluated: V100, V150 and V200 
(percentage target volume receiving 100%, 150% and 200% of the 
prescription dose, respectively). 
Results: For both patients, the MRI guided BT procedure with mould 
was feasible and the reconstruction accuracy was ±1 mm. The 
prescription dose for patient 1 was 78 pulses of 70 cGy, given in 
extended office hours. V100= 97%, V150=61%, V200=22%. Short term 
follow up (8 months): no evidence of disease. The prescription dose 
for patient 2 was 82 pulsesof 70 cGy, given in extended office hours. 
V100= 82%, V150=37%, V200=19%. Short term follow up (9 months): no 
evidence ofdisease. 
Conclusions: MR guided interstitial BT with moulds is feasible and may 
lead to better positioning of catheters with respect to target volume 
and thus better dose distributions. 
 
 ELECTRONIC POSTER: BRACHYTHERAPY TRACK: 
PHYSICS  
  
EP-1338   
An independent check of point dose calculation for commissioning 
a brachytherapy treatment planning system 
D. Piriyasang1, S. Sakulsingharoj1, S. Srisuwan1 
1Ramathibodi Hospital, Diagnostic and Therapeutic Radiology, 
Bangkok, Thailand  
 
Purpose/Objective: To verify the accuracy of an independent point 
dose calculation to validate the dose calculation algorithm (AAPM TG-
43) of a brachytherapy treatment planning system. 
Materials and Methods: Commissioning was performed of the 
Nucletron Oncentra Brachytherapy (v 4.1) treatment planning system. 
The source configuration data of Nucletron 192-Ir-mHDR-V2 and other 
TG-43 parameters, including dose rate constant, geometry factor, 
radial dose function and anisotropy function, were checked for errors 
and anomalies. This data was also entered into RadCalc (v 6.1) 
software for use as an independent point dose calculation method, 
and a manual calculation of treatment time of three sources dwell 
position was compared to that reported by the Oncentra TPS. The 
point dose calculations based on the TG-43 dosimetry protocol were 
also compared to the previously commissioned Nucletron Plato (v 
14.3.7) brachytherapy TPS, and also verified using the brachytherapy 
module in RadCalc. Thirty-four retrospective treatment plans (25 
cervical CA using tandem and ovoids and 9 endometrium CA using 
cylinder and ovoids) were generated using Plato and Oncentra with 
the same planning data sets (normalization, optimization, and 
prescription dose). The plan results, source times and point doses, 
were compared with each system and also exported to RadCalc and 
evaluated using an acceptance criteria of ±2% for agreement. 
Results: The dose computation algorithm appears consistent to within 
less than 2% for Oncentra, Plato and Radcalc, in terms of point doses 
and source times. The total treatment time for Oncentra and Radcalc 
are equal for each patient plan. For Plato and Oncentra, the 
treatment times differ slightly due to differences in the rounding 
methods used to determine the dwell times for each source position. 
An independent, manual treatment time check was also found to be 
within acceptable limits of ±2% for a multiple-source (dwell position). 
Conclusions: The point dose verification for brachytherapy planning 
system was accepted for clinical use. Independent checks using point 
dose calculation software provide a simple, fast and accurate method 
to check TPS. Since patient-specific quality assurance requires a quick 
and simple method, this approach can be confidently used to verify 
the accuracy of dose calculation prior to each patient treatment.  
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